CSI Market
Sign In | Register

Xilio Therapeutics Inc (XLO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access XLO quarterly Cash Flow →
From Xilio Therapeutics Inc through Dec 31 2021, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-35.04
Depreciation & amortization1.54
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue27.88
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation6.94
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-5.85
Noncash Interest Expense-
Fair Value Adjustments Of Warrants And Derivative Liabilities-
Increase Decrease In Operating Lease Right Of Use Asset-
Payment Of Stock Issuance Costs Allocated To Warrants2.28
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-5.00
Increase (Decrease) in Accounts Payable0.15
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.98
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.08
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-4.99
Investing Activities
Capital Expenditures-0.52
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.52
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock40.74
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Preferred Units-
Finance Lease Principal Payments-
Proceeds From Issuance Of Stock Private Placement Net Of Issuance Costs-
Proceeds From Issuance Of Prefunded Warrants And Common Stock Warrants In Connection With A Follow- On Offering Net Of Issuance Costs47.03
Proceeds From Issuance Of Prefunded Warrants In Connection With Follow- On Offering Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Capital Expenditures Incurred But Not Yet Paid-
Settlement Of Liabilities To Issue Common Stock By Issuing Common Stock-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities87.78
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.51
Total Cash Flow82.27
4 historic quarters locked

Sign in to unlock the full Xilio Therapeutics Inc cash flow history.

Sign In Create Free Account

About Xilio Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 23, 2026
  • Source: xlo-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-118550

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License